Retrospective Cohort Study on the Impact of Immunotherapy with depigmented, polymerized Allergen Extract on the Occurrence and Progression of atopic Dermatitis (AD) under Real-life Conditions

被引：0
|
作者：
Mueller, T. [1 ]
Nemat, K. [2 ]
Richter, H. [3 ]
Sager, A. [4 ]
机构：
[1] LETI Pharma GmbH, Ismaning, Germany
[2] Kinderzentrum Dresden, Dresden, Germany
[3] RWS Epidemiol IQVIA, Frankfurt, Germany
[4] LETI Pharma GmbH, Witten, Germany
来源：
ALLERGOLOGIE | 2022年 / 45卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P6.02
引用
收藏
页码：621 / 621
页数：1
相关论文
共 35 条
  • [31] ACT-FASTER: An epidemiological prospective Cohort Study to describe treatment patterns of fulvestrant and exemestane in postmenopausal patients with advanced HR+ breast cancer under real-life conditions in Germany
    Ostermann, H.
    Bruno, B.
    Greiner, W.
    Possinger, K.
    Tesch, H.
    Zaun, S.
    Maass, N.
    ONKOLOGIE, 2011, 34 : 61 - 62
  • [32] ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany
    Maass, Nicolai
    Ostermann, Helmut
    Possinger, Kurt
    Klein, Peter
    Tesch, Hans
    Muehlenhoff, Lars
    Bauerschlag, Dirk O.
    BREAST CARE, 2019, 14 (06) : 401 - 408
  • [33] A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, user-friendliness and patients' acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE)
    Backer, Vibeke
    Bjermer, Leif
    Refvem, Olav Kare
    Soderman, Andreas
    Jones, Spencer
    PRAGMATIC AND OBSERVATIONAL RESEARCH, 2019, 10 : 29 - 39
  • [34] Baseline results from ACT-FASTER, a prospective cohort study exploring treatmentpatterns with fulvestrant and exemestane in postmenopausal patients with advancedhormone-receptor positive breast cancer under real-life conditions in Germany
    Bauerschlag, D.
    Maass, N.
    Greiner, W.
    Possinger, K.
    Tesch, H.
    Zaun, S.
    Klein, P.
    Ostermann, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 18 - 18
  • [35] Baseline results from ACT-FASTER, a prospective cohort study exploring treatment patterns with fulvestrant and exemestane in postmenopausal patients with advanced hormone-receptor positive breast cancer under real-life conditions in Germany
    Ostermann, H.
    Maass, N.
    Possinger, K.
    Tesch, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 264 - 264
1234